Form 4: Hologic Merger Completes, Executive Ownership Changes

Hologic Inc. announces the completion of its merger, resulting in changes to executive beneficial ownership of company securities.

Summary

• This filing reports changes in beneficial ownership for Christiana Stamoulis, a Director at Hologic Inc. (HOLX), following a merger transaction.
• The merger, effective April 7, 2026, involved Hologic, Inc. being acquired by Hopper Parent Inc. through its subsidiary, Hopper Merger Sub Inc.
• Each share of Hologic common stock was converted into $76.00 in cash and one contingent value right (CVR) potentially worth up to $3.00.
• As a result of the merger, Stamoulis no longer beneficially owns any shares of Hologic common stock directly or indirectly.
• Options to purchase Hologic common stock were cancelled and converted into cash payments and/or CVRs, depending on their exercise price relative to the merger consideration.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports on a completed merger transaction and the resulting changes in ownership, rather than providing new operational or financial performance data.

Positives

• The merger provides shareholders with a cash payout of $76.00 per share, plus a potential additional $3.00 per share via a CVR.
• Executive options were converted into cash and/or CVRs, providing value realization for equity awards.

Negatives

• As a result of the merger, the reporting person no longer beneficially owns any shares of Hologic common stock directly or indirectly.
• Options with an exercise price equal to or greater than the sum of the cash consideration and $3.00 were cancelled for no consideration.

Risks

• The contingent value right (CVR) is subject to payment conditions, meaning the additional $3.00 per share may not be realized.
• The filing does not detail specific risks associated with the acquiring entities or the post-merger operational structure.

Future Outlook

The filing primarily reports on a completed transaction and does not contain forward-looking statements or guidance regarding future performance of the acquired entity or the acquirer.

Management Comments

• The merger was completed pursuant to an Agreement and Plan of Merger dated October 21, 2025.
• Each share of Hologic common stock was converted into $76.00 in cash and one contingent value right (CVR) for up to $3.00.
• Outstanding stock options were cancelled and converted into cash and/or CVRs based on their exercise price.

Industry Context

StockSavvy.ai notes that the completion of this merger signifies consolidation within the medical technology sector, a trend driven by the pursuit of scale, innovation, and market share. Such transactions often lead to significant changes in beneficial ownership for key executives and directors as equity awards are settled.

Stakeholder Impact

• Shareholders: Received $76.00 in cash per share and a contingent value right (CVR) with potential for additional cash.
• Employees: Holders of stock options received cash and/or CVRs based on their option terms.
• Management/Directors: Beneficial ownership of Hologic common stock has been extinguished due to the merger.

Next Steps

• The reporting person no longer beneficially owns any shares of Hologic common stock.
• The contingent value right (CVR) may provide additional cash payments if certain conditions are met.

Key Dates

Keywords

Hologic Inc., HOLX, Form 4, Merger, Beneficial Ownership, Stock Options, Contingent Value Right, SEC Filing, Executive Compensation